PDS Biotechnology Corp. Files 8-K Report

Ticker: PDSB · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1472091

Pds Biotechnology Corp 8-K Filing Summary
FieldDetail
CompanyPds Biotechnology Corp (PDSB)
Form Type8-K
Filed DateFeb 5, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00033
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing, Corporate Update

TL;DR

PDS Biotechnology filed an 8-K, likely routine updates or financials.

AI Summary

On February 5, 2025, PDS Biotechnology Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that PDS Biotechnology Corp. is providing updates or submitting required financial documentation to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative or positive events.

Key Numbers

  • 001-37568 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 26-4231384 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • PDS Biotechnology Corp. (company) — Registrant
  • February 5, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 303A College Road East, Princeton, NJ 08540 (address) — Principal Executive Offices
  • Edge Therapeutics, Inc. (company) — Former Company Name

FAQ

What specific "Other Events" are being reported by PDS Biotechnology Corp. in this 8-K filing?

The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item information category.

What "Financial Statements and Exhibits" are included in this 8-K filing?

The excerpt indicates that "Financial Statements and Exhibits" are part of the filing, but does not specify their content.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on February 5, 2025.

What is PDS Biotechnology Corp.'s principal executive office address?

PDS Biotechnology Corp.'s principal executive office is located at 303A College Road East, Princeton, NJ 08540.

Was PDS Biotechnology Corp. previously known by another name?

Yes, PDS Biotechnology Corp. was formerly known as Edge Therapeutics, Inc., with a name change date of September 11, 2009.

Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-02-05 08:05:26

Key Financial Figures

  • $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M

Filing Documents

01

Item 8.01 Other Events. On February 5, 2025, PDS Biotechnology Corporation (the "Company") issued a press release announcing the reaffirmation of the Company's guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line treatment of recurrent and/or metastatic (R/M) HPV16-positive head and neck squamous cell cancer (HNSCC) in the first quarter of this year. In addition, on February 5, 2025, the Company updated its corporate presentation deck. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein. A copy of the corporate presentation deck is filed herewith as Exhibit 99.2 and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated February 5, 2025. 99.2 Corporate Presentation (February 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: February 5, 2025 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.